Immunohistochemical staining of Cytokeratin 5  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Cytokeratin 5 [XM26] Antibody (cGMP).

$ 145.00$ 595.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD115
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG1, kappa

Product NumberDescriptionPrice
QIVD115-0.1ml Size: 0.1 ml, Format: Concentrate $ 145.00
QIVD115-0.5ml Size: 0.5 ml, Format: Concentrate $ 365.00
QIVD115-1ml Size: 1 ml, Format: Concentrate $ 595.00
QIVD115-6ml Size: 6 ml, Format: Predilute $ 225.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD115-0.1ml
Cytokeratin 5 General Information
Alternate Names
Molecular Weight
62.4 kDa
Chromosomal Location
q13.13 [chr: 12] [chr_start: 52514575] [chr_end: 52520530] [strand: -1]
Curated Database and Bioinformatic Data
Gene SymbolKRT5
Entrez Gene ID3852
RefSeq Protein Accession(s)NP_000415
RefSeq mRNA Accession(s); NM_000424
RefSeq Genomic Accession(s)NG_008297; NC_000012
UniProt ID(s)P13647
PharmGKB ID(s)PA30230
KEGG Gene ID(s)hsa:3852
Associated Diseases (KEGG IDs)Epidermolysis bullosa simplex, autosomal recessive 1 (EBSB1) [MIM:601001]: A form of epidermolysis bullosa, a genodermatosis characterized by recurrent blistering and cleavage within basal keratinocytes, fragility of the skin and mucosal epithelia, and erosions caused by minor mechanical trauma. {ECO:0000269|PubMed:11973334}. The disease is caused by mutations affecting the gene represented in this entry.; Epidermolysis bullosa simplex, Dowling-Meara type (DM-EBS) [MIM:131760]: A severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement. {ECO:0000269|PubMed:10730767, ECO:0000269|PubMed:12655565, ECO:0000269|PubMed:1372711, ECO:0000269|PubMed:16786515, ECO:0000269|PubMed:16882168, ECO:0000269|PubMed:21623745, ECO:0000269|PubMed:8757772, ECO:0000269|PubMed:9036937, ECO:0000269|PubMed:9406827, ECO:0000269|PubMed:9989794, ECO:0000269|Ref.18}. The disease is caused by mutations affecting the gene represented in this entry.; Epidermolysis bullosa simplex, with migratory circinate erythema (EBSMCE) [MIM:609352]: A form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands, feet, and legs but spare nails, ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS, with no evidence of tonofilament clumping. The disease is caused by mutations affecting the gene represented in this entry.; Epidermolysis bullosa simplex, Weber-Cockayne type (WC-EBS) [MIM:131800]: A form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin. {ECO:0000269|PubMed:10782015, ECO:0000269|PubMed:12655565, ECO:0000269|PubMed:12707098, ECO:0000269|PubMed:14723728, ECO:0000269|PubMed:15140024, ECO:0000269|PubMed:15347343, ECO:0000269|PubMed:16786515, ECO:0000269|PubMed:16882168, ECO:0000269|PubMed:21623745, ECO:0000269|PubMed:7506097, ECO:0000269|PubMed:7520042, ECO:0000269|PubMed:7688477, ECO:0000269|PubMed:8595431, ECO:0000269|PubMed:8807337, ECO:0000269|PubMed:9804357}. The disease is caused by mutations affecting the gene represented in this entry.; Epidermolysis bullosa simplex, Koebner type (K-EBS) [MIM:131900]: A form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, although it is less severe. {ECO:0000269|PubMed:11407988, ECO:0000269|PubMed:16882168, ECO:0000269|PubMed:21623745, ECO:0000269|PubMed:7534039, ECO:0000269|PubMed:7686424, ECO:0000269|PubMed:9740251, ECO:0000269|PubMed:9989794}. The disease is caused by mutations affecting the gene represented in this entry.; Epidermolysis bullosa simplex, with mottled pigmentation (MP-EBS) [MIM:131960]: A form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and 'mottled' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules. {ECO:0000269|PubMed:10494094, ECO:0000269|PubMed:16882168, ECO:0000269|PubMed:21623745, ECO:0000269|PubMed:8799157}. The disease is caused by mutations affecting the gene represented in this entry.; Dowling-Degos disease 1 (DDD1) [MIM:179850]: An autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails. {ECO:0000269|PubMed:16465624}. The disease is caused by mutations affecting the gene represented in this entry.
General Description of Cytokeratin 5 .
This antibody reacts with cytokeratin 5 intermediate filament protein. Basal cells of human epidermis express acidic cytokeratin 14 and basic cytokeratin 5. Cytokeratin 5 is a 58 kDa protein, which is closely related to cytokeratin 6. Cytokeratin 5 and 6 are expressed in basal cell epithelioma, basal cells of prostate, urothelium, vagina, squamous cell carcinomas of skin, tongue, epiglottis and rectal-anal region. Cytokeratin 5 can be useful in the distinction of mesotheliomas from most adenocarcinomas.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:75
Pretreatment Citrate Buffer pH 6.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-Cytokeratin 5 Antibody Clone: XM26
Host and Isotype: Mouse IgG1, kappa
Recommended Positive Control Sample: Skin
Cellular Localization of Antibody XM26 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were injected with prokaryotic recombinant protein corresponding to 103 amino acid portion of C-terminal region of the human cytokeratin 5 molecule.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Cytokeratin 5 Information for Pathologists

Summary:

Molecular weight is 58 kDa. Major partner is CK14, but related to cytokeratin 6 (antibodies are often to CK5/6). Common antibody is 34BE12. Mutations may cause epidermolysis bullosa simplex (Hum Mutat 2006;27:719), Dowling-Degos disease (Am J Hum Genet 2006;78:510). Important in tooth enamel formation (J Biol Chem 2003;278:20293).

Common Uses By Pathologists:

Helps defines a basal-like subtype of invasive ductal carcinoma of the breast that is usually CK5/6+, ER-, PR-, HER2-, EGFR+ with poorer prognosis (Clin Cancer Res 2006;12:1533); associated with premenopausal African American women (JAMA 2006;295:2492), BRCA1 (J Natl Cancer Inst 2003;95:1482, Mod Pathol 2005;18:1321) and brain metastases (Am J Surg Pathol 2006;30:1097). Defines a DCIS subtype with poorer prognosis (Hum Pathol 2007;38:197). Distinguish breast usual ductal hyperplasia (strong staining) from solid papillary DCIS (negative, Hum Pathol 2006;37:787). p63+ and CK5/6+ poorly differentiated metastatic carcinomas are likely to have squamous carcinoma primaries (Am J Clin Pathol 2001;116:823). Distinguish epithelioid mesothelioma (CK5/6+ cytoplasmic staining with perinuclear enhancement) from lung adenocarcinoma (usually CK5/6 negative, Histopathology 2006;48:223); also in pleural effusions (Diagn Cytopathol 2006;34:801).

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Cytokeratin 5 [XM26] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Chat: See lower right corner. | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Cytokeratin 5 [XM26] Antibody (cGMP).